What "exosomes" means — and the topical vs therapeutic split
Exosomes are extracellular vesicles derived from cultured cells. In aesthetics, you'll encounter products positioned two different ways, and the distinction matters for how a clinic sources, documents, and talks about them. On one side are products positioned for topical and aesthetic use — applied topically, often paired with microneedling or post-procedure protocols. On the other are products positioned for therapeutic use, which carry a very different regulatory and licensing posture.
These are provider-directed use areas, not statements of efficacy — licensed providers determine appropriate use for each patient. This guide does not tell you what exosomes do clinically; it tells you what a compliance-conscious clinic verifies before it ever puts a product on the shelf.
The regulatory reality
That framing — copied directly from how Eventide states it on its own biologics page — is the compliance floor, not the ceiling. It shapes what a practice can honestly say in its own marketing, in patient conversations, and on its intake forms. A clinic should never describe an exosome product as FDA-approved, and should never attach a treatment, cure, or disease claim to it.
What regulation does exist governs how these products are made and handled, not whether the FDA has evaluated them the way an approved drug is evaluated. That's why the documentation section below is the real substance of exosome compliance: in this category, silence reads as risk.
The documentation your clinic should demand
Every question a compliance-conscious buyer raises on a first call should be answerable before you commit. These are the items to require — the same ones a careful medical director will ask for:
- Certificate of Analysis (CoA) and Certificate of Conformance (CoC) — available for every batch, with third-party certified reports.
- 21 CFR Part 1271 compliance — the federal framework covering human cells, tissues, and cellular and tissue-based products, where applicable to the product.
- cGMP manufacturing — current Good Manufacturing Practice, ideally with cleanroom classification (e.g., ISO7) for the manufacturing environment.
- Donor-eligibility screening — documented screening records behind any donor-derived material.
- Full lot traceability — the ability to trace any unit back through its batch, with single-donor, single-batch discipline rather than recycled cell lines.
A quality operation answers these quickly and provides the paperwork on request. A defensive or vague answer tells you something too. This is the same documentation discipline that applies to compounded medications from 503A and 503B pharmacies — the category differs, but the principle is identical: verify how it's made, in writing, every lot.
Red flags when sourcing
- Any claim that the product is FDA-approved, or "FDA-approved to treat" anything. It is not, and a source saying so is a red flag in itself.
- Efficacy or outcome promises — "clinically proven results," "cures," "guaranteed." No clinical outcome should be claimed or guaranteed.
- No CoA/CoC available per lot, or documentation that can't be produced on request.
- No answer on 21 CFR Part 1271, cGMP, or donor screening — or a source that treats the question as an inconvenience.
- Recycled cell lines or vague sourcing — no single-donor, single-batch traceability.
- Pressure to market beyond what the documentation supports — a partner encouraging disease or treatment claims is exposing your license, not helping your business.
State variability
Product availability and permitted use vary by state and by product. Some exosome products are positioned strictly for topical aesthetic application; therapeutic products may be licensed for use only in specific states. There is no single national rule that makes a given exosome product usable everywhere, which is why "it's legal in that state" is never a substitute for "it's compliant in my state, for my license, for this product."
The practical takeaway: match the right product to your state and your license before you buy, and keep the documentation on file. Where a product's therapeutic licensing is limited to certain states, that limit is a fact about the product, not a formality to work around.